Current data demonstrate that despite the PD-L1 protein being over-expressed in over 50% of HNSCC tissues, only 15% of patients will respond to PD-1/PD-L1 inhibitors [214]. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.